Enabling massively scalable, high fidelity,
and truly flexible multiplexing using the nELISA.
- Phenotype A
- Phenotype B
- Phenotype C
Anatomy of the nELISA Platform
Leveraging groundbreaking technology to build an ecosystem of tools,
modalities, and services to dramatically expand access to the proteome.
Using DNA nanotechnology, we transformed the ELISA into a high-throughput proteomics technology.
~200 cytokines on-boarded to-date for comprehensive profiling of the immune secretome.
The world’s fastest & most seamless protein profiling service, with as fast as 1-week turnaround.
Multiplexing without compromise
The nELISA is designed to achieve multiplexing at-scale without the usual trade-offs.
At 10,000+ samples per week per workcell, nELISA brings central lab-throughput to proteomics.
A complete and elegant solution to the cross-reactivity problem in multiplexed immunoassays.
Replacing fixed, incompatible panels with the freedom to pick proteins “à la carte”.
Enabling the study of protein expression, interaction, or modification, in one platform.
Broad profiling meets absolute quantification, all at exquisite precision of <5% CV day-to-day.
Enabled by innovation, the nELISA brings about unparalleled cost efficiency.
Validated by Visionaries.
“Understanding and creating learning models to accelerate drug discovery is challenging. Nomic's nELISA platform allows us to understand, in an unbiased way; proteomics in relation to phenomics.”
VP Biology @ Recursion Pharmaceuticals
“The nELISA has transformed our capabilities and is the primary data stream for our high throughput in vitro and ex vivo experiments. The data dimensionality, quality and turnaround time far surpasses anything we could achieve in house ourselves.”
Associate Director, Myeloid Biology @ Immunai
“The nELISA platform helped us examine our immune assays in more depth, and greater sample number. This greatly opened up what we can see in a complex immune assay, giving us a much better understanding and allowing us to reach conclusions much faster.”
Director of Biologics @ Dren Bio
Nomic Appoints Byron Hewett to Board of Directors
Byron Hewett, a veteran in the lifescience tools space, joins Nomic’s board of directors
Nomic Closes $17 Million Series A
Nomic Closes $17 Million Series A to Develop and Commercialize the World's Highest Throughput Proteomic Platform
Nomic to Provide nELISA to JUMP Cell Painting Consortium
Nomic to Provide nELISA to JUMP Cell Painting Consortium to Measure Protein Secretome for Phenotypic Drug Discovery
Nomic & McGill receive $1M CQDM Grant
Nomic-McGill partnership selected by CQDM for a $1M grant to apply next- generation ELISA in drug discovery